Abstract 445
Aim/Background
As the first phase II trial, it aimed to evaluate and predict the efficacy and safety of S-1 combined with oral leucovorin (S-1/LV) as first-line chemotherapy for patients with advanced gastric cancer (AGC), using S-1 pharmacogenetic pathway approach.
Methods
39 patients orally took S-1 at conventional dose and LV simultaneously at a dose of 25 mg twice daily for a week, within a 2-week cycle. The endpoints were overall response rate (ORR), progression-free survival (PFS), time to failure (TTF), overall survival (OS), disease control rate (DCR), and adverse events (AEs). Peripheral blood was sampled prospectively for baseline plasmic expression of dihydropyrimidine dehydrogenase (DPD), orotate phosphoribosyltransferase (OPRT), thymidine phosphorylase (TP), and thymidylate synthase (TS), CYP2A6 gene polymorphisms, and 5-FU pharmacokinetics.
Results
The ORR and the DCR were 41.0% and 76.9%. The median PFS, median TTF, and median OS were 4.13 (95% CI, 3.44-4.83), 3.70 (2.60-4.80), and 11.40 (7.76-15.05) months. Grade 3 ∼ 4 AEs occurred in only 13 patients, and grade 4 AE (neutropenia) occurred in only one of them. High OPRT/TS (Odd Ratio (OR) 16.962 (1.781-161.581), P = 0.014) and peritoneal metastasis (OR 25.604 (1.852-353.979), P = 0.016) independently predicted responding. High OPRT/DPD (OR 15.566 (1.490-162.605), P = 0.022) independently predicted grade 3 ∼ 4 AEs. Response to S-1/LV (Hazards Ratio (HR) 0.275 (0.124-0.609), P = 0.001) and high area under the curve (AUC0-24h) of 5-FU (HR 0.272 (0.114-0.645), P = 0.003) independently predicted prolonged PFS. Low baseline plasmic DPD (HR 2.726 (1.045-7.113), P = 0.040) and second-line treatment (HR 0.259 (0.091-0.736), P = 0.011) independently predicted prolonged OS. See table. Table:
| Univariate analysis | Multivariate analysis | |||||
|---|---|---|---|---|---|---|
| HR | 95% CI | P | HR | 95% CI | P | |
| PFS/Variates | ||||||
| Response to S-1/LV | 0.011 | 0.001 | ||||
| no | 1 | reference | 1 | reference | ||
| yes | 0.391 | 0.190-0.803 | 0.275 | 0.124-0.609 | ||
| Metastatic/recurrent sites | 0.040 | 0.111 | ||||
| ≤ 2 | 1 | reference | 1 | reference | ||
| 3 | 2.728 | 1.049-7.092 | 1.866 | 0.867-4.013 | ||
| AUC0-24h of 5-FU | 0.026 | 0.003 | ||||
| ≤ 1281.800 | 1 | reference | 1 | reference | ||
| > 1281.800 | 0.404 | 0.182-0.898 | 0.272 | 0.114-0.645 | ||
| TTF/Variates | Univariate analysis | Multivariate analysis | ||||
| HR | 95% CI | P | HR | 95% CI | P | |
| Response to S-1/LV | 0.016 | 0.007 | ||||
| no | 1 | reference | 1 | reference | ||
| yes | 0.434 | 0.220-0.857 | 0.362 | 0.172-0.762 | ||
| Metastatic/recurrent sites | 0.013 | 0.107 | ||||
| ≤ 2 | 1 | reference | 1 | reference | ||
| 3 | 2.487 | 1.210-5.019 | 1.840 | 0.877-3.859 | ||
| AUC0-24h of 5-FU | 0.051 | 0.028 | ||||
| ≤ 1281.800 | 1 | reference | 1 | reference | ||
| > 1281.800 | 0.492 | 0.234-1.033 | 0.403 | 0.179-0.907 | ||
| OS/Variates | Univariate analysis | Multivariate analysis | ||||
| HR | 95% CI | P | HR | 95% CI | P | |
| Baseline CEA (continuous) | 1 | 1.000-1.001 | 0.041 | 1 | 1.000-1.001 | 0.176 |
| Secondline chemotherapy | 0.001 | 0.011 | ||||
| no | 1 | reference | 1 | reference | ||
| Yes | 0.192 | 0.071-0.520 | 0.259 | 0.091-0.736 | ||
| Baseline plasmic DPD | 0.009 | 0.040 | ||||
| ≤ 119.200 pg/ml | 1 | reference | 1 | reference | ||
| > 119.200 pg/ml | 1.014 | 1.003-1.025 | 2.726 | 1.045-7.113 | ||
| Baseline plasmic TP | 0.033 | 0.078 | ||||
| ≤ 137.900 ng/ml | 1 | reference | 1 | reference | ||
| > 137.900 ng/ml | 0.365 | 0.145-0.920 | 0.412 | 0.154-1.104 | ||
Conclusions
S-1/LV demonstrated promising efficacy and satisfactory safety in AGC. Patients with high OPRT/TS, high AUC0-24h of 5-FU, low DPD and second-line chemotherapy may benefit most from S-1/LV.
Clinical trial identification
NCT02090153
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
Vitamin D3 (cholecalciferol) acts as a negative regulator of breast cancer cell invasiveness in the absence of activation of classical VDR signalling
Presenter: MD Musharraf Hossain
Session: Poster presentation 1
Resources:
Abstract
VCP/p97 inhibition is a therapeutic strategy to overcome drug resistance in ovarian and pancreatic cancers
Presenter: Yuliana Astuti
Session: Poster presentation 1
Resources:
Abstract
Upregulation of the interleukin 17/granulocyte-colony stimulating factor/fibroblast growth factor axis and its correlation with indoleamine 2,3-dioxygenase in breast cancer
Presenter: Kosuke Kawaguchi
Session: Poster presentation 1
Resources:
Abstract
Updated analysis: Phase II trial of irinotecan plus S-1 (IRIS) with cetuximab (IRIS/Cet) in pre-treated patients with KRAS wild type metastatic colorectal cancer (mCRC): HGCSG0902
Presenter: Ayumu Hosokawa
Session: Poster presentation 1
Resources:
Abstract
Updated analysis: observational cohort study of 1st line bevacizumab combined with chemotherapy in metastatic colorectal cancer (HGCSG0802): Comparison of infusional FU/oxaliplatin (OX) + BV and oral FU/OX + BV
Presenter: Yoshito Komatsu
Session: Poster presentation 1
Resources:
Abstract
Tuberculosis exposure and the risk of cancer
Presenter: Vincent Yi-Fong Su
Session: Poster presentation 1
Resources:
Abstract
Triple negative breast cancer and androgen receptor expression: a forerunner for a novel hormonal approach
Presenter: Prameela Chelakkot G
Session: Poster presentation 1
Resources:
Abstract
Treatment of radiation induced side-effects in prostate cancer patients with hyperbaric oxygen therapy
Presenter: HAYATO Takeda
Session: Poster presentation 1
Resources:
Abstract
Tolerability and efficacy of neoadjuvant chemotherapy with three-weekly interval methotrexate, doxorubicin, vinblastine and cisplatin regimen for patients with locally advanced bladder cancer
Presenter: Satoko Arai
Session: Poster presentation 1
Resources:
Abstract
To compare the efficacy and safety of pazopanib and sunitinib in metastatic renal cell carcinoma (RCC) of Chinese population
Presenter: Michelle Fong Ting Chan
Session: Poster presentation 1
Resources:
Abstract